Literature DB >> 20378110

Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.

M Angeles Martínez-Zamora1, Montserrat Creus, Dolors Tassies, Albert Bové, Juan Carlos Reverter, Francisco Carmona, Juan Balasch.   

Abstract

Antiphospholipid syndrome patients with recurrent miscarriage have an impairment in fibrinolysis demonstrated by prolonged clot lysis time (CLT) that cannot be attributed to differences in thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels. Patients with unexplained recurrent miscarriage have an impairment in fibrinolysis demonstrated by increased CLT, that can be at least partly explained by higher TAFI antigen levels.
Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378110     DOI: 10.1016/j.fertnstert.2010.02.032

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion.

Authors:  Ping Fang; Decheng Cai; Lijun Du; Fei Shen; Chengfang Zhang; Meijuan Li
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.